# A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Finding useful health information on the Internet can be difficult, but we’re here to help. This page gathers quality information from trusted sources. You can learn more about the disease, visit handpicked websites, and find resources to help you in your daily life. Need more information? Click the menu on the left to find more!

 

Acute myeloid leukemia

Acute Non Lymphoblastic Leukemia
Get Update

Clinical Trials

This information is provided by ClinicalTrials.gov

Search Clinical Trials
Displaying 111-120 of 663 results.
Decitabine,Cytarabine and Arsenic Trioxide for Acute Myeloid Leukemia With p53 Mutations
Status: Not yet recruiting
Last Changed: Jan 04, 2018
First Received: Dec 22, 2017
Disease(s): Acute Myeloid Leukemia, P53 Mutation
Intervention(s): Decitabine, Arsenic Trioxide, Cytarabine
Locations: Ruijin Hospital North, Shanghai, China
Ruijin Hospital, Shanghai, China
Shanghai Institute of Hematology, Shanghai, China
Testing a New Chemotherapy Drug, KRT-232 (AMG 232) in Combination With Standard Chemotherapy (Cytarabine and Idarubicin) in Patients With Acute Myeloid Leukemia
Status: Not yet recruiting
Last Changed: Mar 03, 2020
First Received: Dec 09, 2019
Disease(s): Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome
Intervention(s): Cytarabine, Idarubicin, Idarubicin Hydrochloride, MDM2 Inhibitor AMG-232
CPX-351 and Glasdegib for Newly Diagnosed Acute Myelogenous Leukemia With MDS Related Changes or Therapy-related Acute Myeloid Leukemia
Status: Not yet recruiting
Last Changed: Jan 18, 2020
First Received: Jan 18, 2020
Disease(s): Acute Myelogenous Leukemia (AML) Due to Therapy, Acute Myeloid Leukemia With Myelodysplasia-Related Changes
Intervention(s): Glasdegib, CPX-351
Locations: Chao Family Comprehensive Cancer Center, University of California, Irvine, Orange, California, United States
CAR-T Cells Therapy in Relapsed/Refractory Acute Myeloid Leukemia
Status: Recruiting
Last Changed: Aug 16, 2019
First Received: Mar 22, 2018
Disease(s): Relapsed/Refractory Acute Myeloid Leukemia(AML)
Intervention(s): CART therapy in Acute myeloid leukemia(AML)
Locations: Southern Medical University Zhujiang Hospital, Guangdong, Guangdong, China
DLAAG in the Treatment of Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome With Blast Excess
Status: Recruiting
Last Changed: Nov 29, 2017
First Received: Nov 29, 2017
Disease(s): Acute Myeloid Leukemia, Myelodysplastic Syndrome
Intervention(s): Decitabine, Cytarabine, All-transretinoic acid, G-CSF
Locations: Beijing Friendship Hospital, Beijing, China
Fujian Medical University Union Hospital, Fuzhou, China
The People's Hospital of Guangxi Zhuang Autonomous Region, Nanning, China
Shanghai Tong Ren hospital, Shanghai, China
The center hospital of Shanghai Fengxian District, Shanghai, China
... and 2 other locations.
Phase I/II Trial of CPX-351 + Palbociclib in Patients With Acute Myeloid Leukemia
Status: Recruiting
Last Changed: Aug 05, 2019
First Received: Feb 19, 2019
Disease(s): Acute Myeloid Leukemia, AML
Intervention(s): Palcociclib, CPX-351
Locations: Cleveland Clinic, Case Comprehensive Cancer Center, Cleveland, Ohio, United States
Psychological Intervention Mobile App for Patients With AML
Status: Recruiting
Last Changed: Nov 13, 2019
First Received: Dec 13, 2017
Disease(s): Acute Myeloid Leukemia
Intervention(s): Usual Care, Psychological intervention
Locations: Dana Farber Cancer Institute, Boston, Massachusetts, United States
Massachusetts General Hospital, Boston, Massachusetts, United States
Investigation of the Gut Microbiota in Patients With Acute Myeloid Leukemia
Status: Recruiting
Last Changed: Mar 20, 2019
First Received: Mar 20, 2019
Disease(s): Acute Myeloid Leukemia, Cachexia
Intervention(s): collection of clinical data and biological samples
Locations: UCLouvain, Brussels, Belgium
A Study of LAM-003 in Patients With Acute Myeloid Leukemia
Status: Recruiting
Last Changed: Dec 11, 2018
First Received: Feb 08, 2018
Disease(s): Oncology, Acute Myeloid Leukemia
Intervention(s): Open Label LAM-003
Locations: Yale University, New Haven, Connecticut, United States
University of Maryland, Baltimore, Maryland, United States
Dana Farber Cancer Institute, Boston, Massachusetts, United States
Hackensack Meridien Health, Hackensack, New Jersey, United States
Weill Cornell Medical College, New York, New York, United States
... and 2 other locations.
CD123-Directed Autologous T-Cell Therapy for Acute Myelogenous Leukemia (CATCHAML)
Status: Not yet recruiting
Last Changed: Mar 24, 2020
First Received: Mar 24, 2020
Disease(s): Acute Myeloid Leukemia
Intervention(s): CD123-CAR T, Cyclophosphamide, Fludarabine, Mesna, Rituximab
Locations: St. Jude Children's Hospital, Memphis, Tennessee, United States